Press Release

Printer Friendly VersionView printer-friendly version << Back

Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference

NEWARK, Calif., Nov. 1, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the Stifel 2017 Healthcare Conference taking place on November 14-15th at the Lotte New York Palace Hotel in New York, NY.

Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

The Protagonist Therapeutics presentation is scheduled for Wednesday, November 15 at 10:15 am ET.

A live and archived audio webcast of the presentation can be accessed by visiting the Investors page of Protagonist Therapeutics corporate website at

About Protagonist Therapeutics

Protagonist Therapeutics is a clinical development-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. Lead oral peptide candidates, PTG-100 and PTG-200, are based on this approach. The alfa-4-beta-7 integrin antagonist PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company plans to initiate clinical trials with the interleukin-23 receptor antagonist PTG-200 in 2017 as a potential treatment for Crohn's disease.  The company recently entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200.  Protagonist is also developing an injectable hepcidin mimetic, PTG-300, for the treatment of rare diseases such as beta-thalassemia and myelodysplastic syndromes (MDS). PTG-300 is currently being studied in a Phase 1 clinical trial.

Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland, Australia. For further information, please visit


View original content with multimedia:

SOURCE Protagonist Therapeutics, Inc.

Joan Kureczka, Kureczka/Martin Associates, +1-415-821-2413,; or Investors, Marcy Nanus, The Trout Group, +1-646-378-2927,